SUMMARY Plasma concentrations of gastrin, somatostatin, neurotensin, and enteroglucagon were measured by radioimmunoassay in normal 30-and 45-day-old neonates and age-matched infants with confirmed idiopathic hypertrophic pyloric stenosis. Plasma gastrin and somatostatin concentrations were similar in both groups, whereas neurotensin and enteroglucagon were significantly lower in the pyloric stenosis group.
Since the original anatomical description of hypertrophic pyloric stenosis, this disorder has been recognised as the most common congenital anomaly of the gastrointestinal tract requiring surgical correction. The aetiology of the condition is still unknown. Although various hypotheses have been suggested recent interest has been focused on the gastrointestinal hormone gastrin. It is not however agreed whether plasma gastrin is raised in infant pyloric stenosis. '-4 Apart from gastrin, other gastrointestinal hormones have received little attention. In the present study we have investigated the concentrations of neurotensin, enteroglucagon, somatostatin, as well as gastrin in infants with pyloric stenosis.
Neurotensin is a newly discovered vasoactive peptide,5 which was first found in the synaptosomal and microsomal subcellular fractions of brain tissue, suggesting a role as a central neurotransmitter. 6 However, in the distal small intestine, neurotensin In man many conditions which tend to cause malabsorption of food are associated with high circulating enteroglucagon and neurotensin. However, both enteroglucagon and neurotensin are low in starvation, where there is gut atrophy.14 Concentrations are also low in cord blood and rise sharply after oral nutrition, although they remain low in infants who are not enterally fed. 15 Somatostatin is another peptide that was first discovered in the brainl6 and subsequently found to occur in the gastrointestinal tract. Infusion of somatostatin into humans has shown that pharmacologically the peptide possesses powerful inhibitory effects on a number of diverse physiological functions,'7 including gastric and pancreatic secretions. Patients and methods Twelve term infants, without gastrointestinal disease (6 each at 30 and 45 days post-partum) and 12 term infants with pyloric stenosis (6 each at 31 ± 1.6 and 44 ± 3 days post-partum) were studied with the approval of the ethics committee. The weights of the infants at the time of sampling (before the operation) were comparable (controls and pyloric stenosis at 30 days, 4 ± 0.3 and 4 ± 0-2 kg, and at 45 days 4 5 ± 0.3 and 4-3 ± 0*2 kg respectively). Also, birthweights in the two groups were not different (control, 3.6 ± 0.2 kg and pyloric stenosis 3*7 ± 0. I kg). The mean daily food intake in the two groups were: control, 184 ± 9 ml/kg, pyloric stenosis, 143 ± 6 ml/kg, P<0.005).
The diagnosis of pyloric stenosis was made on clinical history (vomiting and constipation) and by radiological examination; the diagnosis was confirmed at operation. The duration of the symptoms was for a mean of 5 ± 1 days.
All infants were 'formula fed' (Guigoz) at 4-hourly intervals. In each group samples were taken immediately before feeding.
All the blood was taken before operation. Venous blood samples (2 ml) were collected into heparincoated tubes containing approtinin (Trasylol, Bayer: 2000 KIU); the plasma was separated after centrifugation at 4°C within 20 minutes of collection. All samples were stored at -20°C until assay. Plasma neurotensin was measured by radioimmunoassay as previously described,8 with some modifications and using a new antibody which is C-terminally directed. This antibody was raised to pure synthetic neurotensin and detected differences between individual plasma samples of 3 pmol/l with 95% confidence. The assay showed no cross-reaction with other gut hormones. As human enteroglucagon is not available in pure form, an indirect radioimmunoassay method was used. Two glucagon antibodies were used,'8 one of which (R59, N-terminal nonspecific) appeared to cross-react totally with gut glucagon and fully measured pure porcine enteroglucagon (glicentin). The second antiserum RCS5, C-terminal directed appeared to be fairly specific for pancreatic glucagon and gave zero readings in total pancreatectomised patients. The enteroglucagon levels were derived from the difference between these two assays. Changes of 6 pmol/l were detectable (with 95% confidence) in this assay system. Plasma gastrin and somatostatin were measured by previously described radioimmunoassays.'9 20 Statistical analyses were perfotmed using the non-parametric Wilcoxon's rank sum test, but for ease of comparison, mean and standard error of the mean (SEM) are given in the text.
Results
Mean plasma enteroglucagon concentrations (Table) in the infants with pyloric stenosis were less than half those of the control infants, at both 30 and 45 days (both P<0.01). These concentrations (both control and pyloric stenosis) by far exceeded the normal adult enteroglucagon concentration (37 ± 5 pmol/l).
The neurotensin concentrations (Table) were, similarly, significantly reduced in the infants with pyloric stenosis, at both 30 and 45 days post-partum (P <0 * 01 and P <0 * 05 respectively).
The Figure shows the individual enteroglucagon and neurotensin values in the control and pyloric stenosis infants (values at 30 and 45 days were combined). The mean enteroglucagon and neurotensin concentrations in the pyloric stenosis group were significantly (P <0.001) lower than the corresponding control group.
Plasma gastrin and somatostatin concentrations (combined 30 and 45 days) were not significantly different in the two groups (gastrin, 67 ± 13.5 and 41 ± 7-5 pmol/l, somatostatin 39 ± 7 and 44 ± 5.5 pmol/l, in the infants with pyloric stenosis and controls, respectively). 
